Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges

Jeffrey Glennon, Diane Purper-Ouakil, Mireille Bakker, Alessandro Zuddas, Pieter Hoekstra, Ulrike Schulze, Josefina Castro-Fornieles, Paramala J. Santosh, Celso Arango, Michael Kölch, David Coghill, Itziar Flamarique, Maria J. Penzol, Mandy Wan, Macey Murray, Ian C. K. Wong, Marina Danckaerts, Olivier Bonnot, Bruno Falissard, Gabriele MasiJörg M. Fegert, Stefano Vicari, Sara Carucci, Ralf W. Dittmann, Jan K. Buitelaar

Risultato della ricerca: Contributo in rivistaArticolo in rivista

16 Citazioni (Scopus)


In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology.
Lingua originaleEnglish
pagine (da-a)1149-1160
Numero di pagine12
Stato di pubblicazionePubblicato - 2014


  • Conduct disorder
  • Pharmacovigilance
  • Psychopharmacology
  • Randomised clinical trials
  • Risperidone


Entra nei temi di ricerca di 'Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges'. Insieme formano una fingerprint unica.

Cita questo